At Birth, Children with Type 1 Diabetes Show Different Molecular Patterns Based on Genetic Risk

A new study found that newborns who later develop Type 1 diabetes have distinct patterns of genetic regulation and proteins in their cord blood, and these patterns differ depending on whether they carry high-risk or low-risk genes for the disease.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

Scientists discovered that children destined to develop Type 1 diabetes show unique molecular signatures at birth, detectable in cord blood samples.
The molecular patterns differ significantly between children with high-risk versus low-risk genetic profiles for Type 1 diabetes.
These patterns involve immune system pathways, DNA damage responses, and protein interactions that may influence disease development later in life.
This research provides clues to how genetic risk shapes early biological processes, potentially setting the stage for Type 1 diabetes years before symptoms appear.

What the Researchers Studied

Scientists using the ABIS birth cohort—a population-based study tracking babies born in Southeast Sweden—investigated whether molecular differences present at birth could help explain why some children develop Type 1 diabetes later in life. They focused on two key measures: epigenetic markers (chemical tags that affect how genes are regulated) and circulating proteins in newborns' blood.

The team examined cord blood samples from three groups: children who later developed Type 1 diabetes and carried high-risk HLA genes, children who later developed Type 1 diabetes but carried low-risk HLA genes, and healthy children who never developed the disease. HLA genes are part of the immune system's recognition machinery and are known to influence Type 1 diabetes risk.

Different Genetic Risk Groups Show Different Molecular Patterns

When researchers compared the molecular data, they found that children with high-risk HLA genes who developed Type 1 diabetes showed a distinct pattern of molecular changes compared to those with low-risk genes who also developed the disease. This suggests that different biological pathways may lead to Type 1 diabetes depending on a person's genetic background.

Children carrying high-risk HLA genes showed networks centered around immune signaling, DNA damage responses, and antigen presentation—the mechanisms by which immune cells recognize and attack targets. Children with low-risk genes displayed different patterns, with more spread-out networks involving chemokine signaling (immune cell communication), inflammasome activation (inflammatory responses), cellular stress, and vesicle trafficking (how cells move materials internally).

Comparing Disease Risk Groups to Healthy Controls

The researchers also compared both disease-risk groups to healthy newborns. High-risk carriers who developed Type 1 diabetes showed highly immune-centered molecular architectures that integrated HLA class II interactions—a key component of how the immune system presents antigens to immune cells. This suggests their immune systems may be 'primed' differently at birth.

Low-risk carriers who developed Type 1 diabetes showed more distributed molecular patterns compared to healthy controls, with involvement of chemokine pathways and cellular stress responses, indicating a different set of biological processes at play.

Why This Matters

This study reveals that Type 1 diabetes does not have a single biological signature at birth. Instead, different genetic risk profiles appear linked to different molecular patterns in newborns—patterns that may shape how susceptibility to the disease develops over time.

By identifying these early molecular differences, researchers gain insights into the biological mechanisms that contribute to Type 1 diabetes development. Understanding which pathways matter for which genetic groups could eventually inform strategies for earlier identification or intervention. However, this research is foundational; much more work is needed to determine how these birth signatures relate to disease progression and whether they could be used clinically in the future.

Evidence label

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.